Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17953993 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL13293157 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL9547901 | 0.84 | ALDH1A1 (0.43) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL15933413 | 0.82 | PAOX (0.44) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL13410354 | 0.82 | GABRR1 (0.46) | ALDH1A1CYP1A2TDP1CHRM1CA1 | |
| SCHEMBL14197461 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNASLC15A2GABRPGABRD | |
| SCHEMBL12040134 | 0.81 | CYP1A2 (0.68) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL2344610 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNASLC15A2GABRPGABRD | |
| SCHEMBL2352613 | 0.81 | CYP1A2 (0.68) | ALDH1A1CYP1A2TDP1LMNASLC15A2 | |
| SCHEMBL12658700 | 0.81 | CYP1A2 (0.68) | CYP1A2LMNASLC15A2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309560-A1 | SOLUBLE LIQUID COMPOSITIONS OF SAFLUFENACIL, METHOD OF PREPARATION AND USE THEREOF | ADAMA AGAN LTD. (IL) | 2023-10-05 | — | — | US | disclosed |
| CN-115074189-A | Process solution composition for treating macromolecules | 东友精细化工有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-9376381-B2 | High penetration prodrug compositions of peptides and peptide-related compounds | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-06-28 | — | — | US | disclosed |
| EP-2322631-B1 | Methods and compositions for the prodcution of orthogonal tRNA-aminoacyl-tRNA synthetase pairs | SCRIPPS RESEARCH INST (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2336105-B9 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL (JP) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013109939-A1 | METHODS OF MAKING AND USING NANOSTRUCTURES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20120202243-A1 | IN Vivo Incorporation of Unnatural Amino Acids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114648-B2 | In vivo incorporation of unnatural amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-14 | — | — | US | disclosed |
| US-8030074-B2 | In vivo incorporation of unnatural amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2322631-A1 | In vivo incorporation of unnatural amino acids | The Scripps Research Institute (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20080261311-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | THE SCRIPPS RESEARCH INSTITUTE and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-10-23 | — | — | US | disclosed |
| US-20080227152-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-18 | — | — | US | disclosed |
| CN-100402474-C | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL CO (JP) | 2008-07-16 | — | — | CN | disclosed |
| US-20080166783-A1 | Translation system for biosynthesis of insulin like growth factor | THE SCRIPPS RESEARCH INSTITUTE and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-10 | — | — | US | disclosed |
| US-7368275-B2 | Orthogonal tRNA synthetase that aminoacylates with reduced efficiency; lower km and recognizes selector codon in mRNA | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080014250-A1 | Bifunctionalized polysaccharides | PROTEINS AND PEPTIDES MANAGEMENT (FR) | 2008-01-17 | — | — | US | disclosed |
| CN-101100429-A | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL COMPANY LIMT (JP) | 2008-01-09 | — | — | CN | disclosed |
| US-20070117184-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | THE SCRIPPS RESEARCH INSTITUTE | 2007-05-24 | — | — | US | disclosed |
| US-20070060543-A1 | Aminated complex-type sugar chain derivatives and process for the production thereof | GLYTECH, INC. (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1347861-A | Process for producing carbonyl or hydroxy compound | SUMITOMO CHEMICAL CO (JP) | 2002-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014250-A1 | Bifunctionalized polysaccharides | CD44, SI, HDGF | ALDH1A1 1537/4885CYP1A2 2913/4885TDP1 4234/4885 |
| US-20230309560-A1 | SOLUBLE LIQUID COMPOSITIONS OF SAFLUFENACIL, METHOD OF PREPARATION AND USE THEREOF | SLCO4C1, OTC, SORD | ALDH1A1 187/4885CYP1A2 1690/4885TDP1 841/4885 |
| US-20080261311-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | AARS1, NSUN3, TRMT1 | ALDH1A1 4462/4885CYP1A2 4692/4885TDP1 2420/4885 |
| US-20070060543-A1 | Aminated complex-type sugar chain derivatives and process for the production thereof | OSTC, C9, FUT4 | ALDH1A1 1323/4885CYP1A2 2054/4885TDP1 4858/4885 |
| US-20070117184-A1 | Translation systems with orthogonal aminoacyl tRNA synthetase; membrane proteins | AARS1, NSUN3, TRMT1 | ALDH1A1 4462/4885CYP1A2 4692/4885TDP1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.